Glychek 40 Tablet contains Gliclazide 40mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating insulin secretion from the pancreatic beta cells, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glychek 40 is prescribed as an adjunct to diet and exercise when blood glucose levels cannot be adequately controlled by lifestyle modifications alone. The medication helps reduce both fasting and postprandial blood glucose concentrations, contributing to the prevention of long-term diabetic complications such as neuropathy, nephropathy, and retinopathy. It is essential to monitor blood glucose levels regularly during therapy to adjust the dosage appropriately and minimize the risk of hypoglycemia, a common adverse effect characterized by symptoms such as sweating, dizziness, and confusion. Caution is advised in patients with hepatic or renal impairment, and it should be used with care in elderly patients. Glychek 40 Tablet is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Patient adherence to prescribed diet, exercise, and medication regimen is crucial for optimal therapeutic outcomes.